Oncologist hires may 'finish the battle for radiation' in Corner Brook, says advocate
On Friday the Newfoundland and Labrador government announced two radiation oncologists have been recruited to work at the Western Memorial Regional Hospital in Corner Brook.
Gerald Parsons, who has been fighting for better cancer care on the west coast for decades as co-chair of the Western Regional Hospital Action Committee, said he'll be pleased as soon as the first oncologist starts work.
"Hopefully this will finish the battle for radiation," he told CBC Radio's Newfoundland Morning.
Years ago he had no choice but to take his wife to St. John's for cancer treatment and said radiation services in Corner Brook would have made a world of difference.
WATCH | Radiation in Corner Brook means west coast families can stay close to home:
N.L. finds its health staff for radiation unit in Corner Brook
5 days ago
The wait for radiation treatment in Corner Brook has been a long fight for people like Gerald Parsons. The opening of the new Western Memorial Regional Hospital came with the promise of on-site radiation, but not the professionals to staff it. Now, the province has announced, two new radiation oncologists have been recruited with treatment expected to begin in the fall.
"They say one of the biggest healing processes with cancer is having family around you," he said. "We spent five weeks in St. John's at a hotel."
For Parsons, radiation services on the west coast has been a long time coming.
"It's been a year since [the Western Memorial Regional Hospital] opened up and the service is still not there. All the equipment is here," said Parsons.
In Friday's statement, the Newfoundland and Labrador Health Services said the two oncologists will start work in the summer and fall, and radiation oncology services will be rolled out in three phases.
The ongoing first phase provides CT simulations to eligible patients for radiation planning purposes. Phase two is hoped to begin in late August and include consultations and follow-up appointments in Corner Brook.
The third and final phase of the radiation service roll-out "includes radiation services beginning and continuing to scale up as recruitment and onboarding of specialized staff progresses," said the statement.
Parsons said the announcement is a step closer to his ultimate goal of better health-care services in western Newfoundland.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
12 minutes ago
- CBC
New portal launches to help people experiencing intimate partner violence in York Region
WARNING: This story may affect those who have experienced intimate partner violence or know someone affected by it. York Region has a new online portal called EmpowerWeb, encouraging people to seek help much earlier when in an abusive relationship. Many people can be stuck in abusive situations for decades before they are able to get the help needed, Helena Kameka, president of Abuse Hurts, told CBC Radio's Metro Morning. "When I finally was able to come upon the help I needed, it was life-changing for me, and we want that same life-changing thing sooner and more effectively for women today," Kameka said. Abuse Hurts, an organization that provides support to abuse victims, created the new portal, which is available at every public library across York Region. Kameka hopes this will help as the region grapples with an intimate partner violence epidemic. Intimate partner violence was declared an epidemic in York Region in 2023 with statistics showing an upward trend in incidents involving family violence and intimate partner violence, according to York Region's website. There were over 6,500 incidents of intimate partner violence in York Region in 2024, York Regional Police said in their annual statistics report. New portal hopes to 'empower' abuse victims to get help EmpowerWeb offers a range of services like children's aid, shelters, legal aid, and support services to ensure users have access to several services depending on need. The goal for EmpowerWeb is to provide trauma-informed assistance, said Kameka, noting the information is co-created by people with lived experience to ensure it is "less likely to re-traumatize a survivor as they're going through the material." WATCH | She survived domestic violence. Now she's giving hope to others: Understanding different social services using interactive tools built into the portal can help overcome the "fear of unknown" and encourage users to know what service is best for them, Kameka said. EmpowerWeb includes safety precautions like clearing browser history and techniques to divert from your online location to ensure the abuser is unaware. Creating a new Gmail or Hotmail account that your partner cannot access is also encouraged when using the portal, Kameka said. Lived experience inspired to start this initiative Abuse Hurts helps thousands of women each year to escape abusive situations and personal experiences of the workers help understand the survivors troubles better, Kameka said. "We understand, and it's an amazing feeling to be there for someone else when people weren't there for us," Kameka said. Numbers on intimate partner violence have remained steady between 2023-24 with 77 per cent of the accused being men, York Regional Police annual statistics reports said. Abuse Hurts was first launched in 1993 by Ellen Campbell, who is a survivor of abuse, and they continue to expand services to provide better aid for victims. Kameka says if similar portals like EmpowerWeb with knowledge and resources for abuse survivors existed earlier, it would have enabled her to receive help sooner.
National Post
8 hours ago
- National Post
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Article content Phase 3 data show Bausch + Lomb's LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes LUMIFY delivers noticeable results in one minute, lasts up to eight hours and is the No. 1 doctor-recommended redness reliever brand; more info at Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness. Article content 'Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,' 1 said John Ferris, president, Consumer, Bausch + Lomb. 'This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.' Article content In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY. Article content The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed. Article content 'The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. Article content About the LUMIFY Brand Article content The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. Before LUMIFY, redness relievers relied on the same ingredients for decades and were associated with well-known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers formulated with low-dose brimonidine tartrate 0.025% that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. In June 2025, Bausch + Lomb launched LUMIFY Preservative Free eye drops in the U.S. For more information on the LUMIFY brand, visit Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content Facebook Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content References Article content ©2025 Bausch + Lomb. Article content Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Kristy Marks Article content Article content Article content
CTV News
8 hours ago
- CTV News
UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025
The logo for UnitedHealth Group appears above a trading post on the floor of the New York Stock Exchange, April 17, 2025. (AP Photo/Richard Drew, file) UnitedHealth delivered disappointing second-quarter earnings and went conservative with its 2025 forecast as soaring medical costs continue to swamp insurers. The health care giant said Tuesday expenses that have jumped beyond what it expected when it set coverage prices will continue to pressure its performance. But the company expects a return to earnings growth in 2026. UnitedHealth now expects adjusted earnings of at least $16 per share in 2025 after withdrawing its previous forecast in May. It had started 2025 with expectations of making up to $30 per share. For the full year, analysts forecast earnings of $20.64 per share, according to the data firm FactSet. UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. The Eden Prairie, Minnesota, company also operates a growing Optum business that provides care and technology support. In May, the company withdrew its 2025 forecast due to higher-than-expected medical costs, and CEO Andrew Witty departed the company abruptly. He was replaced by Chairman Stephen Hemsley, who was the UnitedHealth CEO for more than a decade until 2017. That came after the company took the rare step in April of cutting its forecast. That pushed UnitedHealth shares down $130 in its worst single-day performance in over 25 years. Hemsley promised in June that UnitedHealth would establish a 'prudent' 2025 earnings outlook when it detailed second-quarter results. He also said the company had underestimated care activity and cost trends, but improvements were being made. In the second quarter, UnitedHealth reported adjusted earnings of $4.08 per share on $111.6 billion in total revenue. Analysts expected earnings of $4.48 per share on $111.5 billion in revenue, according to FactSet. The company's profit fell 19% to $3.41 billion even as revenue rose 13%. Medical costs, the company's biggest operating expense, jumped 20% to $78.6 billion in the quarter. UnitedHealth is normally the first insurer to report earnings every quarter. But this summer, it followed competitors like Elevance Health Inc. and Centene Corp. that have lowered their annual forecasts and delivered disappointing results. Several insurers say they have been hit by medical costs that are growing faster than expected. Companies have seen a rise in expensive emergency rooms visits and growing prescription drug costs, especially from expensive cancer treatments and gene therapy. They've also seen a rise in behavioral health care, which includes the treatment of mental health conditions and substance use disorders. UnitedHealth shares slid about more than 3% to $272.30 before the opening bell Tuesday. That price topped $630 last November to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. Shares are down 44% so far this year. The Dow Jones Industrial Average, of which UnitedHealth is a member, has climbed 5%. Tom Murphy, The Associated Press
